Background: Mental health disorders are a significant global disease burden, and the stigma towards people with them is the strongest obstacle to improving mental health and dealing with an enormous public health problem. Montenegro is a small country with a conservative society and a deeply ingrained patriarchy. The aim of this study was to determine attitudes toward mental health disorders in the general population of Montenegro and identify the influence of socio-demographic characteristics. Methods: The research was conducted as an online cross-sectional study. The questionnaire included a demographic section and a section on attitudes towards mental health as well as the CAMI scale (community attitudes toward mental health disorders). Results: The subjective opinions of the respondents showed a lack of awareness about mental health campaigns in the country. Stigma towards mental health was present in younger and more highly educated populations. Conclusions: The obtained data indicate the magnitude of the problem when it comes to the stigma towards mental health disorders in Montenegro. Furthermore, there is a need for a systematic nationwide and metacentric study, identifying and exploring a wide range of individual factors contributing to the stigma of mental health problems.
Pharmacogenomics is a crucial area in neuropsychopharmacology, offering a scientific foundation for precision medicine in treating psychiatric disorders, particularly schizophrenia spectrum disorders (SSD). Patients with SSD exhibit significant variability in their response to antipsychotic drugs, ranging from lack of efficacy to severe adverse drug reactions. This variability is largely due to genetic differences affecting drug metabolism (e.g., CYP450 enzymes such as CYP2D6 and CYP1A2) and drug targets (e.g., dopamine D2 and serotonin 2A receptors). For instance, an individual’s metabolizer status can dramatically alter drug concentrations, influencing both therapeutic effectiveness and the risk of side effects, such as weight gain and extrapyramidal symptoms. Recent advancements including multi-gene panels and multi-omics approaches (genomics, epigenomics, and metabolomics) are deepening our understanding of these complex drug responses. While promising case studies and clinical trial data highlight the predictive power of pharmacogenetics, its routine clinical integration faces substantial challenges. These include the need for standardized protocols, more robust real-world evidence, and improved omics literacy among healthcare providers. Overcoming these hurdles through collaborative efforts and technological advancements is essential to fully achieve the potential of pharmacogenomics in personalizing antipsychotic treatment, ultimately leading to improved patient outcomes and more effective mental healthcare.